STANDEX INTERNATIONAL CORP/DE/ — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that STANDEX INTERNATIONAL CORP/DE/ filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Jun 30, 2020 | $142.31M | Aug 25, 2020 |
| FY2020 | Mar 31, 2020 | $187.04M | Aug 25, 2020 |
| FY2020 | Dec 31, 2019 | $190.59M | Aug 25, 2020 |
| FY2020 | Sep 30, 2019 | $196.44M | Aug 25, 2020 |
| FY2020 | Jun 30, 2019 | $209.20M | Aug 25, 2020 |
| FY2020 | Mar 31, 2019 | $216.77M | Aug 25, 2020 |
| FY2020 | Dec 31, 2018 | $219.50M | Aug 25, 2020 |
| FY2020 | Sep 30, 2018 | $217.53M | Aug 25, 2020 |
| FY2019 | Jun 30, 2018 | $203.47M | Aug 27, 2019 |
| FY2019 | Mar 31, 2018 | $192.15M | Aug 27, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Jun 30, 2017 | $217.09M | Aug 28, 2017 |
| FY2017 | Mar 31, 2017 | $184.72M | Aug 28, 2017 |
| FY2017 | Dec 31, 2016 | $173.85M | Aug 28, 2017 |
| FY2017 | Sep 30, 2016 | $179.60M | Aug 28, 2017 |
| FY2017 | Jun 30, 2016 | $193.78M | Aug 28, 2017 |
| FY2017 | Mar 31, 2016 | $177.47M | Aug 28, 2017 |
| FY2017 | Dec 31, 2015 | $181.95M | Aug 28, 2017 |
| FY2017 | Sep 30, 2015 | $198.40M | Aug 28, 2017 |
| FY2016 | Jun 30, 2015 | $199.78M | Aug 25, 2016 |
| FY2016 | Mar 31, 2015 | $181.00M | Aug 25, 2016 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $315.25M | Aug 4, 2025 |
| FY2025 | Jun 30, 2024 | $282.00M | Aug 4, 2025 |
| FY2025 | Jun 30, 2023 | $285.10M | Aug 4, 2025 |
| FY2024 | Jun 30, 2022 | $269.95M | Aug 2, 2024 |
| FY2023 | Jun 30, 2021 | $241.26M | Aug 4, 2023 |
| FY2020 | Jun 30, 2020 | $46.55M | Aug 25, 2020 |
| FY2020 | Mar 31, 2020 | $58.11M | Aug 25, 2020 |
| FY2020 | Dec 31, 2019 | $66.45M | Aug 25, 2020 |
| FY2020 | Sep 30, 2019 | $68.28M | Aug 25, 2020 |
| FY2020 | Jun 30, 2019 | $70.08M | Aug 25, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $55.76M | Aug 4, 2025 |
| FY2025 | Jun 30, 2024 | $73.07M | Aug 4, 2025 |
| FY2025 | Jun 30, 2023 | $138.99M | Aug 4, 2025 |
| FY2024 | Jun 30, 2022 | $61.39M | Aug 2, 2024 |
| FY2023 | Jun 30, 2021 | $36.47M | Aug 4, 2023 |
| FY2020 | Jun 30, 2020 | $1.84M | Aug 25, 2020 |
| FY2020 | Mar 31, 2020 | ($6.32M) | Aug 25, 2020 |
| FY2020 | Dec 31, 2019 | $12.24M | Aug 25, 2020 |
| FY2020 | Sep 30, 2019 | $12.44M | Aug 25, 2020 |
| FY2020 | Jun 30, 2019 | $12.39M | Aug 25, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $93.55M | Aug 4, 2025 |
| FY2025 | Jun 30, 2024 | $101.74M | Aug 4, 2025 |
| FY2025 | Jun 30, 2023 | $171.09M | Aug 4, 2025 |
| FY2024 | Jun 30, 2022 | $88.29M | Aug 2, 2024 |
| FY2023 | Jun 30, 2021 | $59.17M | Aug 4, 2023 |
| FY2022 | Jun 30, 2020 | $60.53M | Aug 5, 2022 |
| FY2021 | Jun 30, 2019 | $79.48M | Aug 13, 2021 |
| FY2020 | Jun 30, 2018 | $78.14M | Aug 25, 2020 |
| FY2019 | Jun 30, 2017 | $56.92M | Aug 27, 2019 |
| FY2018 | Jun 30, 2016 | $70.34M | Aug 28, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Jun 30, 2013 | $4.40M | Feb 3, 2014 |
| FY2013 | Jun 30, 2012 | $4.40M | Feb 3, 2014 |
| FY2013 | Jun 30, 2011 | $4.00M | Feb 3, 2014 |
| FY2012 | Jun 30, 2010 | $3.60M | Sep 4, 2012 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $193.36M | Aug 4, 2025 |
| FY2025 | Jun 30, 2024 | $169.60M | Aug 4, 2025 |
| FY2025 | Jun 30, 2023 | $172.34M | Aug 4, 2025 |
| FY2024 | Jun 30, 2022 | $169.89M | Aug 2, 2024 |
| FY2023 | Jun 30, 2021 | $163.06M | Aug 4, 2023 |
| FY2022 | Jun 30, 2020 | $148.50M | Aug 5, 2022 |
| FY2021 | Jun 30, 2019 | $150.33M | Aug 13, 2021 |
| FY2020 | Jun 30, 2018 | $140.68M | Aug 25, 2020 |
| FY2019 | Jun 30, 2017 | $145.03M | Aug 27, 2019 |
| FY2018 | Jun 30, 2016 | $170.22M | Aug 28, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $69.60M | Aug 4, 2025 |
| FY2025 | Jun 30, 2024 | $92.66M | Aug 4, 2025 |
| FY2025 | Jun 30, 2023 | $90.80M | Aug 4, 2025 |
| FY2024 | Jun 30, 2022 | $77.72M | Aug 2, 2024 |
| FY2023 | Jun 30, 2021 | $83.58M | Aug 4, 2023 |
| FY2022 | Jun 30, 2020 | $47.24M | Aug 5, 2022 |
| FY2021 | Jun 30, 2019 | $73.35M | Aug 13, 2021 |
| FY2020 | Jun 30, 2018 | $64.93M | Aug 25, 2020 |
| FY2019 | Jun 30, 2017 | $63.44M | Aug 27, 2019 |
| FY2018 | Jun 30, 2016 | $80.32M | Aug 28, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $1.57B | Aug 4, 2025 |
| FY2025 | Jun 30, 2024 | $1.01B | Aug 4, 2025 |
| FY2024 | Jun 30, 2023 | $1.02B | Aug 2, 2024 |
| FY2023 | Jun 30, 2022 | $934.44M | Aug 4, 2023 |
| FY2022 | Jun 30, 2021 | $962.22M | Aug 5, 2022 |
| FY2021 | Jun 30, 2020 | $930.88M | Aug 13, 2021 |
| FY2020 | Jun 30, 2019 | $921.89M | Aug 25, 2020 |
| FY2019 | Jun 30, 2018 | $916.94M | Aug 27, 2019 |
| FY2018 | Jun 30, 2017 | $867.68M | Aug 28, 2018 |
| FY2017 | Jun 30, 2016 | $690.46M | Aug 28, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $711.68M | Aug 4, 2025 |
| FY2025 | Jun 30, 2024 | $621.50M | Aug 4, 2025 |
| FY2025 | Jun 30, 2023 | $607.45M | Aug 4, 2025 |
| FY2025 | Jun 30, 2022 | $499.34M | Aug 4, 2025 |
| FY2022 | Jun 30, 2021 | $506.43M | Aug 5, 2022 |
| FY2021 | Jun 30, 2020 | $461.63M | Aug 13, 2021 |
| FY2020 | Jun 30, 2019 | $464.31M | Aug 25, 2020 |
| FY2019 | Jun 30, 2018 | $450.80M | Aug 27, 2019 |
| FY2018 | Jun 30, 2017 | $408.66M | Aug 28, 2018 |
| FY2017 | Jun 30, 2016 | $369.96M | Aug 28, 2017 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $610.34M | Aug 4, 2025 |
| FY2025 | Jun 30, 2024 | $281.28M | Aug 4, 2025 |
| FY2024 | Jun 30, 2023 | $264.82M | Aug 2, 2024 |
| FY2023 | Jun 30, 2022 | $267.91M | Aug 4, 2023 |
| FY2022 | Jun 30, 2021 | $278.05M | Aug 5, 2022 |
| FY2021 | Jun 30, 2020 | $271.22M | Aug 13, 2021 |
| FY2020 | Jun 30, 2019 | $273.84M | Aug 25, 2020 |
| FY2020 | Jun 30, 2018 | $204.09M | Aug 25, 2020 |
| FY2018 | Jun 30, 2017 | $242.69M | Aug 28, 2018 |
| FY2018 | Jun 30, 2016 | $157.35M | Aug 28, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $1.13B | Aug 4, 2025 |
| FY2025 | Jun 30, 2024 | $1.09B | Aug 4, 2025 |
| FY2024 | Jun 30, 2023 | $1.03B | Aug 2, 2024 |
| FY2023 | Jun 30, 2022 | $901.42M | Aug 4, 2023 |
| FY2022 | Jun 30, 2021 | $852.49M | Aug 5, 2022 |
| FY2021 | Jun 30, 2020 | $827.66M | Aug 13, 2021 |
| FY2020 | Jun 30, 2019 | $818.28M | Aug 25, 2020 |
| FY2019 | Jul 1, 2018 | $760.40M | Aug 27, 2019 |
| FY2019 | Jun 30, 2018 | $761.43M | Aug 27, 2019 |
| FY2018 | Jun 30, 2017 | $716.61M | Aug 28, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $104.54M | Aug 4, 2025 |
| FY2025 | Jun 30, 2024 | $154.20M | Aug 4, 2025 |
| FY2024 | Jun 30, 2023 | $195.71M | Aug 2, 2024 |
| FY2023 | Jun 30, 2022 | $104.84M | Aug 4, 2023 |
| FY2022 | Jun 30, 2021 | $136.37M | Aug 5, 2022 |
| FY2021 | Jun 30, 2020 | $118.81M | Aug 13, 2021 |
| FY2020 | Jun 30, 2019 | $93.15M | Aug 25, 2020 |
| FY2019 | Jun 30, 2018 | $109.60M | Aug 27, 2019 |
| FY2019 | Jun 30, 2017 | $88.57M | Aug 27, 2019 |
| FY2019 | Jun 30, 2016 | $121.99M | Aug 27, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $552.52M | Aug 4, 2025 |
| FY2025 | Jun 30, 2024 | $148.88M | Aug 4, 2025 |
| FY2024 | Jun 30, 2023 | $173.44M | Aug 2, 2024 |
| FY2023 | Jun 30, 2022 | $174.83M | Aug 4, 2023 |
| FY2022 | Jun 30, 2021 | $199.49M | Aug 5, 2022 |
| FY2021 | Jun 30, 2020 | $199.15M | Aug 13, 2021 |
| FY2020 | Jun 30, 2019 | $197.61M | Aug 25, 2020 |
| FY2019 | Jun 30, 2018 | $193.77M | Aug 27, 2019 |
| FY2018 | Jun 30, 2017 | $191.98M | Aug 28, 2018 |
| FY2017 | Jun 30, 2016 | $92.11M | Aug 28, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 4 | Aug 4, 2025 |
| FY2025 | Jun 30, 2024 | 6 | Aug 4, 2025 |
| FY2025 | Jun 30, 2023 | 11 | Aug 4, 2025 |
| FY2024 | Jun 30, 2022 | 5 | Aug 2, 2024 |
| FY2023 | Jun 30, 2021 | 3 | Aug 4, 2023 |
| FY2020 | Jun 30, 2020 | 0 | Aug 25, 2020 |
| FY2020 | Mar 31, 2020 | 0 | Aug 25, 2020 |
| FY2020 | Dec 31, 2019 | 0 | Aug 25, 2020 |
| FY2020 | Sep 30, 2019 | 1 | Aug 25, 2020 |
| FY2020 | Jun 30, 2019 | 1 | Aug 25, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 4 | Aug 4, 2025 |
| FY2025 | Jun 30, 2024 | 6 | Aug 4, 2025 |
| FY2025 | Jun 30, 2023 | 11 | Aug 4, 2025 |
| FY2024 | Jun 30, 2022 | 5 | Aug 2, 2024 |
| FY2023 | Jun 30, 2021 | 2 | Aug 4, 2023 |
| FY2020 | Jun 30, 2020 | 0 | Aug 25, 2020 |
| FY2020 | Mar 31, 2020 | 0 | Aug 25, 2020 |
| FY2020 | Dec 31, 2019 | 0 | Aug 25, 2020 |
| FY2020 | Sep 30, 2019 | 1 | Aug 25, 2020 |
| FY2020 | Jun 30, 2019 | 0 | Aug 25, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 11.99M | Aug 4, 2025 |
| FY2025 | Jun 30, 2024 | 11.76M | Aug 4, 2025 |
| FY2024 | Jun 30, 2023 | 11.74M | Aug 2, 2024 |
| FY2023 | Jun 30, 2022 | 11.82M | Aug 4, 2023 |
| FY2022 | Jun 30, 2021 | 12.04M | Aug 5, 2022 |
| FY2021 | Jun 30, 2020 | 12.24M | Aug 13, 2021 |
| FY2020 | Jun 30, 2019 | 12.33M | Aug 25, 2020 |
| FY2019 | Jun 30, 2018 | 12.71M | Aug 27, 2019 |
| FY2018 | Jun 30, 2017 | 12.66M | Aug 28, 2018 |
| FY2017 | Jun 30, 2016 | 12.67M | Aug 28, 2017 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $15.03M | Aug 4, 2025 |
| FY2025 | Jun 30, 2024 | $13.90M | Aug 4, 2025 |
| FY2025 | Jun 30, 2023 | $12.99M | Aug 4, 2025 |
| FY2024 | Jun 30, 2022 | $12.25M | Aug 2, 2024 |
| FY2023 | Jun 30, 2021 | $11.45M | Aug 4, 2023 |
| FY2022 | Jun 30, 2020 | $10.61M | Aug 5, 2022 |
| FY2021 | Jun 30, 2019 | $9.83M | Aug 13, 2021 |
| FY2020 | Jun 30, 2018 | $8.89M | Aug 25, 2020 |
| FY2019 | Jun 30, 2017 | $7.85M | Aug 27, 2019 |
| FY2018 | Jun 30, 2016 | $6.85M | Aug 28, 2018 |